Skip to main content

COVID 19 Updates from RheumNow

Social

COVID-19 Does alot of Damage via thrombotic complications - a role for complement or autoantibody mediated thrombotic microangiopathy? #COVID19 https://t.co/33R8WxE5C0

Dr. John Cush @RheumNow ( View Tweet )

1 year 4 months ago
Grand Rounds tomorrow at Rutgers - Im Lecturing on “Disease Modifying and Biologic Use for COVID-19 & the Cytokine Storm Syndrome” https://t.co/FYsr77a68Z Meeting ID: 934 0443 3549

Dr. John Cush @RheumNow ( View Tweet )

1 year 4 months ago
“Middle-high level of RF-IgM could lead to false-positive reactivity of SARS-CoV-2 IgM “ As more people want SARS-CoV2 antibody testing, I am afraid this will give people a false sense of security ⁦@RheumNow⁩ ⁦@ACRheum⁩ NCBI - NLM - NIH https://t.co/vkjWRJQV27
1 year 4 months ago
Check out a great Grand Rounds by Dr. Len Calabrese @LCalabreseDO on "IL-6 in Health & Disease" - great 30 min lecture and great Q&A session - Bravo Lenny! https://t.co/eWTKotQya3

Dr. John Cush @RheumNow ( View Tweet )

1 year 4 months ago
Case report of a stable GPA patient treated with pred and Rituxan on 3/5, developed COVID Sxs next day, progressed to high fever, resp failue, mech ventilaion, Rx with antivirals, HCQ; extubated day 20, negative PCR x2 and discharged day 29. https://t.co/SSSKRbYK2R

Dr. John Cush @RheumNow ( View Tweet )

1 year 4 months ago
World Scleroderma Found Recs on COVID 1) SSc w/ Lung dz may be at risk; 2) Cont Rx & avoid SSc lapse in Rx; 3) SSc pts dont need testing unless Sx+; 4) ACE/ARBs BP meds continued; 5) Initiating preventative Rx w/ HCQ is not recommended https://t.co/8BUE6tLLTi

Dr. John Cush @RheumNow ( View Tweet )

1 year 4 months ago
On May 1st the FDA issued "emergency use authorization" for intravenous use of Remdesivir in patients hospitalised with suspected/confirmed severe COVID-19 infection - defined as SpO2 ≤ 94%, need for O2, mech ventilation, or ECMO. https://t.co/XnBaclhPKm

Dr. John Cush @RheumNow ( View Tweet )

1 year 4 months ago
Pilot study of COVID+ pts treated with antiviral therapy PLUS either Baricitinib or HCQ x2wks shows no changes in clinical/lab outcomes with HCQ/v but better outcomes with Bari for death (0 v 4), CRP *8-->1mg/dl) & discharges (55% v8%) compared to HCQ https://t.co/sTqYHMNOGG

Dr. John Cush @RheumNow ( View Tweet )

1 year 4 months ago
NYC, NYU COVID infected Rheum pts (n 86 RA, PsA, AS, PsO, IBD); 16% Hospitalized. Hosp pts were more likely to be older, w/ HTN, DM, COPD, on Pred, HCQ, MTX, but less likely to be on JAKi, biologic, TNFi (vs ambulatory) https://t.co/UCVndBDc7r https://t.co/ZEk1PFEkXA
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
ACR has published COVID-19 Recs -American College of Rheumatology Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID‐19 Pandemic by Mikuls Johnson Fraenkel Arasaratnam Baden Bermas Chatham https://t.co/wwpslcLXx2

Dr. John Cush @RheumNow ( View Tweet )

1 year 4 months ago
×